Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of "Buy" by Analysts

Key Points

• Analysts have given Krystal Biotech, Inc. (NASDAQ:KRYS) an average rating of "Buy", with one strong buy, seven buy, and one hold rating among them.
• The average twelve-month price objective set by brokerages for Krystal Biotech is $210.75, with price targets ranging from $166.00 to $240.00
• Krystal Biotech reported $1.29 earnings per share for the last quarter, exceeding the consensus estimate of $1.08, along with revenue of $96.04 million.

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have earned an average rating of "Buy" from the nine analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $210.75.

KRYS has been the subject of several recent analyst reports. Guggenheim lowered their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Chardan Capital reiterated a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday, August 5th. HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th. Bank of America reduced their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Finally, Citigroup reiterated a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares in the company, valued at $226,208,400. The trade was a 0.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

A number of large investors have recently made changes to their positions in KRYS. LPL Financial LLC grew its stake in shares of Krystal Biotech by 156.8% during the 4th quarter. LPL Financial LLC now owns 2,946 shares of the company's stock valued at $462,000 after purchasing an additional 1,799 shares during the period. Wells Fargo & Company MN lifted its position in shares of Krystal Biotech by 21.3% during the 4th quarter. Wells Fargo & Company MN now owns 16,928 shares of the company's stock valued at $2,652,000 after buying an additional 2,972 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Krystal Biotech by 1.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after buying an additional 121 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Krystal Biotech by 5.7% during the 4th quarter. Bank of Montreal Can now owns 3,325 shares of the company's stock valued at $521,000 after buying an additional 179 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Krystal Biotech by 1.8% during the 4th quarter. Legal & General Group Plc now owns 69,425 shares of the company's stock valued at $10,876,000 after buying an additional 1,261 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Trading Up 4.0%

Shares of Krystal Biotech stock opened at $149.34 on Thursday. The firm has a market capitalization of $4.32 billion, a P/E ratio of 30.35 and a beta of 0.70. The business has a fifty day simple moving average of $142.78 and a two-hundred day simple moving average of $155.14. Krystal Biotech has a 12 month low of $122.80 and a 12 month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. Analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.